<DOC>
	<DOCNO>NCT02078297</DOCNO>
	<brief_summary>The goal project study mechanism involve dysregulation immune system observe skin subject psoriasis . This do analyze specific immune cell well gene protein expression small skin sample ( biopsy ) patient psoriasis . These result compare skin healthy subject without psoriasis .</brief_summary>
	<brief_title>IL-17 Role Variants Psoriasis</brief_title>
	<detailed_description>A total 80 subject psoriasis currently use systemic treatment , least one psoriatic plaque trunk proximal limb also resistant treat psoriasis area recruit . These subject classify follow 5 group accord localization resistant area : scalp psoriasis ( 20 subject ) , pustular palmo-plantar psoriasis ( 10 subject ) , non-pustular palmo-plantar psoriasis ( 10 subject ) , elbow psoriasis ( 20 subject ) low leg psoriasis ( 20 subject ) . At Day 0 visit , severity psoriasis evaluate use body surface area ( BSA ) Psoriasis Area Severity Index ( PASI ) . After appropriate washout period , 80 subject two skin biopsy : one plaque locate trunk proximal limbs one plaque locate area resistant treatment ( scalp , palms/soles , elbow low leg ) . Each biopsy split half . One part use limited immunohistochemistry panel additional staining perform sample pustular palmo-plantar psoriasis non-pustular palmo-plantar psoriasis subject localize IL-17A IL-23 produce cell . The half use gene expression analysis use Reverse-Transcription-Polymerase Chain Reaction ( RT-PCR ) subject include follow gene : IL-23 ( p40 &amp; p19 ) , IL-17A Human Acidic Ribosomal Protein ( HARP ) . In addition , expression specific gene interest analyze use RT-PCR subject pustular palmo-plantar psoriasis non-pustular palmo-plantar psoriasis . Moreover , four skin biopsy collect 10 healthy volunteer RT-PCR ( IL-23 ( p40 &amp; p19 ) , IL-17A HARP ) . One biopsy collect trunk another one palm sole . A third fourth biopsy collect additional area ( scalp , elbow low limb ) . Gene expression plaque area resistant treatment ( scalp , palm , elbow , low leg ) compare gene expression plaque trunk area upper low limb . A total 30 subject 80 also one two additional skin biopsy . The 10 subject pustular palmo-plantar psoriasis 10 subject non-pustular palmo-plantar psoriasis one additional biopsy involve skin palm one plaque trunk limb cell isolation cell analysis order explore mechanism involve increased expression IL-17A without concurrent increase IL-23 . Ten subject psoriasis vulgaris trunk upper limb without pustular non-pustular palmo-plantar psoriasis also additional biopsy perform lesional skin . Following inflammatory cell extraction , flow cytometry combine cell surface marker intra-cytoplasmic staining use study IL-17A IL-23 T cell , granulocytes/mastocytes/macrophages Ag-presenting cell . If enough cell harvest , three antibody panel analyze follow order use flow cytometry : T cell panel , granulocytes / mastocyte / macrophage panel antigen present cell ( APC ) panel . All panel also evaluate anti-CD45 ( cluster differentiation ) antibody viability test ( Aqua live/dead ) . Results flow cytometry compare biopsy palm subject pustular non-pustular palmo-plantar psoriasis , trunk proximal limbs subject pustular non-pustular palmo-plantar psoriasis trunk proximal limbs subject psoriasis vulgaris . All skin biopsy perform Day 0 visit optional study visit ( Day 10 ) perform suture removal skin biopsy necessary . In addition , circulate plasma level IL-17A measure subject healthy volunteer order compare IL-17A level 5 group subject psoriasis healthy subject . Moreover , correlation IL-17A level PASI explore .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subject , male female , age 18 year old screen visit . 2 . Subject history psoriasis least 6 month ( apply healthy volunteer ) . 3 . Subject psoriasis trunk and/or upper limb and/or thighs area suitable skin biopsy ( apply healthy volunteer ) . 4 . Subject palmoplantar pustular psoriasis palmoplantar nonpustular psoriasis psoriasis scalp elbow low limbs suitable two skin biopsy ( apply healthy volunteer ) . 5 . Female subject willing use effective contraceptive method least 30 day Day 0 least Day 10 . Effective contraceptive method : 1 . Barrier method condom , sponge diaphragm combine spermicide foam , gel cream ; 2 . Hormonal contraception ( oral , intramuscular , implant transdermal ) include DepoProvera , Evra Nuvaring ; 3 . Intrauterine device ( IUD ) ; 4 . Sterilization tubal ligation , hysterectomy vasectomy ; 5 . Postmenopausal state least 1 year 6 . Samesex partner ; 7 . Abstinence . 6 . Female subject childbearing potential must negative urine pregnancy test Screening visit . 7 . Subjects must able willing provide write informed consent comply requirement study protocol . 1 . Female subject pregnant lactating . 2 . Subject use topical treatment psoriasis ( except non medicate emollient ) last 14 day Day 0 exception hydrocortisone desonide face , groin ( include genitals ) inframammary area well shampoos contain tar , salicylic acid , zinc pyrithione . 3 . Subject use UltraViolet ( UV ) B phototherapy excessive sun exposure le 14 day Day 0 . 4 . Subject use non biological systemic therapy treatment psoriasis ( include Psoralen UltraViolet A ( PUVA ) therapy ) , systemic steroid systemic immunosuppressant le 28 day Day 0 . Investigational non biologics agent must discontinue least 28 day 5 half life prior Day 0 ( whichever longer ) . 5 . Subject currently participate clinical trial experimental drug device . 6 . Subject use biological therapy treatment psoriasis le 90 day Day 0 . 7 . Subject take require oral injectable corticosteroid . Inhaled corticosteroid stable medical condition allow . Subjects use oral injectable corticosteroid le 28 day Day 0 exclude . 8 . Subject know hepatitis B hepatitis C viral infection . 9 . Subject know immune deficiency immunocompromised currently use plan use anti retroviral therapy time study . 10 . Subject take anticoagulant medication ( v.g . heparin , LMW ( low molecular weight ) heparin , warfarin , antiplatelets ( NSAID aspirin consider antiplatelets ) ) contra indication skin biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>IL-23</keyword>
	<keyword>IL-17A</keyword>
	<keyword>Skin biopsy</keyword>
</DOC>